Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer.

ABSTRACT:

Purpose

Molecular subtyping for pancreatic cancer has made substantial progress in recent years, facilitating the optimization of existing therapeutic approaches to improve clinical outcomes in pancreatic cancer. With advances in treatment combinations and choices, it is becoming increasingly important to determine ways to place patients on the best therapies upfront. Although various molecular subtyping systems for pancreatic cancer have been proposed, consensus regarding proposed subtypes, as well as their relative clinical utility, remains largely unknown and presents a natural barrier to wider clinical adoption.

Experimental design

We assess three major subtype classification schemas in the context of results from two clinical trials and by meta-analysis of publicly avai

SUBMITTER: Rashid NU 

PROVIDER: S-EPMC6942634 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature